The U.S. litigation regarding Pradaxa has been settled for the hefty amount of $650 million. The fact was ceded by Boehringer Ingelheim. Pradaxa stands for dabigatran etexilate mesylate. The...
European regulators have dealt a setback to a novel heart failure drug under development by Novartis. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended...